Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13081727 | 0.90 | PTPN12 (0.48) | KMT2AMEN1POLBPTPN12PTPN22 | |
| SCHEMBL13081954 | 0.82 | PLG (0.49) | KMT2AMEN1POLBMAPT | |
| SCHEMBL8337812 | 0.81 | PTPN12 (0.43) | KMT2AMEN1POLBPTPN12PTPN22 | |
| SCHEMBL10492163 | 0.77 | PTPN12 (0.77) | KMT2AMEN1POLBPTPN12PTPN22 | |
| SCHEMBL10492165 | 0.77 | PTPN12 (0.77) | KMT2AMEN1POLBPTPN12PTPN22 | |
| SCHEMBL8337257 | 0.77 | KMT2A (0.49) | KMT2AMEN1POLBMAPT | |
| SCHEMBL8288295 | 0.72 | MEN1 (0.55) | KMT2AMEN1POLBMAPT | |
| SCHEMBL8334697 | 0.72 | KMT2A (0.53) | KMT2AMEN1POLBPTPN12PTPN22 | |
| SCHEMBL3892576 | 0.71 | HIF1AN (0.81) | KMT2AMEN1PTPN22MAPT | |
| SCHEMBL13056328 | 0.71 | HIF1AN (0.81) | KMT2AMEN1PTPN22MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | APAF1, ANTXR2, SERPINB1 | KMT2A 3456/4885MEN1 2660/4885POLB 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.